Other Clinical Trial - Invasive Left Heart Catheterization Registry

Status Completed

Clinical Trial Summary

Retrospectively enrolled suspicious of heart failure with preserved ejection fraction (HFpEF) patients who underwent left heart catheterization with the measurement of left ventricular end-diastolic pressure.

Clinical Trial Description

Heart failure (HF) with preserved ejection fraction (HFpEF) remains a poorly understood clinical syndrome without effective targeted therapies. The clinical syndrome of HFpEF develops from a complex interaction of several risk factors such as aging, obesity, hypertension, myocardial ischemia, and arterial stiffness that cause organ dysfunction and, ultimately, clinical symptoms. Although the H2FPEF and HFA-PEFF scores have recently been proposed to estimate the probability of HFpEF in patients suffering from unexplained dyspnea, diagnosing HFpEF remains still challenging. The aim of the current registry was to evaluate the role of invasive left heart catheterization with the measurement of left ventricular end-diastolic pressure (LVEDP) in suspicious of HFpEF patients. ;

Study Design

Related Conditions & MeSH terms

Heart Failure
Heart Failure With Preserved Ejection Fraction
Left Ventricular Diastolic Dysfunction

Clinical Trial Details

NCT number	NCT04505449
Study type	Observational
Source	Samsung Medical Center
Contact
Status	Completed
Phase
Start date	December 13, 2019
Completion date	March 31, 2021

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05839730` - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT05095688` - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting	`NCT06379152` - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05676684` - Dapagliflozin, Spironolactone or Both for HFpEF	Phase 2/Phase 3
Recruiting	`NCT04153136` - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)	Phase 2
Recruiting	`NCT06114498` - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05715697` - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT04745013` - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart	N/A
Completed	`NCT05126836` - Cilostazol for HFpEF	Phase 2
Completed	`NCT05586828` - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting	`NCT04594499` - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting	`NCT05204238` - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed	`NCT04535726` - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting	`NCT03550235` - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed	`NCT04633460` - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure	Phase 2
Completed	`NCT06228807` - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting	`NCT05284617` - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF	Phase 2
Recruiting	`NCT05562063` - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients	Phase 4
Recruiting	`NCT06027307` - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation	Phase 3
Withdrawn	`NCT05322616` - Single-Ascending Dose Study of JK07 in Subjects With HFpEF	Phase 1